TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17329061

Group type: EXPERIMENTAL
Intervention: Groningen active living model (GALM) intervention group (n=79)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Waiting-list control group (CG) (n=102)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 181
Study: 16224680

Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA) patients
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 43
Study: 12403858

Group type: EXPERIMENTAL
Intervention: Home-based asthma education program (8 weekly sessions)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 95
Study: 10547391

Group type: EXPERIMENTAL
Intervention: Fenretinide (200 mg/day for 5 years)
Number of subjects: 2972

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 2972
Study: 8636520

Group type: EXPERIMENTAL
Intervention: CPAP of 5 cm H2O (PEEP) with flow-by trigger mode
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CPAP of 5 cm H2O (PEEP) with demand-valve trigger mode
Number of subjects: 12

Group type: COMPARATOR
Intervention: Zero end-expiratory pressure (ZEEP)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Flow-by trigger mode
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Demand-valve trigger mode
Number of subjects: 12
Study: 2179478

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette‐Guérin (BCG) therapy administered in weekly scarifications up to 3 years
Number of subjects: 48

Group type: COMPARATOR
Intervention: No further therapy (Control group)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette‐Guérin (BCG) therapy
Number of subjects: 48
Study: 7471341

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg buccally)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31923061

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% plus ketorolac
Number of subjects: 71

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 71
Study: 30391194

Group type: EXPERIMENTAL
Intervention: Oral selexipag
Number of subjects: 34
Study: 27764781

Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg once daily in combination with thoracic radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 fractions/week) followed by IV cisplatin and vinorelbine chemotherapy
Number of subjects: 16
Study: 25873050

Group type: EXPERIMENTAL
Intervention: Oral iron treatment at 6 mg/kg/day plus dietary advice
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo plus dietary advice
Number of subjects: 150
Study: 23564916

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 1184

Group type: COMPARATOR
Intervention: n-3FA supplement
Number of subjects: 1184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1184
Study: 21269779

Group type: EXPERIMENTAL
Intervention: 20mg hydrocortisone
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 18506446

Group type: EXPERIMENTAL
Intervention: Low-dose 40 mg Depo-Medrol soaked Gelfoam applied over the affected nerve root after discectomy
Number of subjects: 57

Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 57
Study: 17214891

Group type: EXPERIMENTAL
Intervention: Implicit computer-based decision aid (DARTS II)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Explicit computer-based decision aid (DARTS II)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Paper-based guidelines (control)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: All arms of the trial
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Computer-based decision aids
Number of subjects: 29
Study: 16813586

Group type: EXPERIMENTAL
Intervention: Combination pre-operative chemoradiotherapy (CRT)
Number of subjects: 0
Study: 15459400

Group type: EXPERIMENTAL
Intervention: Active screening approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening for chlamydia in men
Number of subjects: 0
Study: 10916444

Group type: EXPERIMENTAL
Intervention: GB + C (gastric band with cuff)
Number of subjects: 80

Group type: COMPARATOR
Intervention: GB - C (gastric band without cuff)
Number of subjects: 80
Study: 8832772

Group type: EXPERIMENTAL
Intervention: ORG-2766 (40 mg/day)
Number of subjects: 0
Study: 1485505

Group type: EXPERIMENTAL
Intervention: 3-in-one block with general anesthesia
Number of subjects: 182

Group type: COMPARATOR
Intervention: General anesthesia only
Number of subjects: 182
Study: 3917702

Group type: EXPERIMENTAL
Intervention: Potassium chloride supplementation (64 mmol potassium chloride a day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29978378

Group type: EXPERIMENTAL
Intervention: RBE-enriched porridge (35 g, including 2 g RBE) with water
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: RBE-enriched porridge (35 g, including 2 g RBE) with milk
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: RBE oil (2 g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 12
Study: 28410760

Group type: EXPERIMENTAL
Intervention: Universal glove and gown use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Improvement in hand hygiene compliance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduction in HCW-patient contact rates
Number of subjects: 0
Study: 25348594

Group type: EXPERIMENTAL
Intervention: Endoscopic fundoplication
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI) therapy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both treatment options (endoscopic fundoplication and PPI therapy)
Number of subjects: 47
Study: 23059790

Group type: EXPERIMENTAL
Intervention: Intrathecal methylprednisolone acetate (MPA) 60 mg + lidocaine 60 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lidocaine 60 mg only (Control)
Number of subjects: 10
Study: 22093120

Group type: EXPERIMENTAL
Intervention: Dornase alpha inhaled after airway clearance techniques
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dornase alpha inhaled before airway clearance techniques
Number of subjects: 20
Study: 17905237

Group type: EXPERIMENTAL
Intervention: Smokers (n=72)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Nonsmokers (n=58)
Number of subjects: 130
Study: 17919254

Group type: EXPERIMENTAL
Intervention: Permanent acrylic resilient denture liner dentures (RLD)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conventional heat‐activated acrylic resin dentures (ARD)
Number of subjects: 74
Study: 15297090

Group type: EXPERIMENTAL
Intervention: Nutritional intervention by a specialized nutritional team (nurse and dietician)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group (standard regime)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Nutritional intervention and control
Number of subjects: 212
Study: 11718219

Group type: EXPERIMENTAL
Intervention: Tc-99m THY
Number of subjects: 39

Group type: COMPARATOR
Intervention: Tc-99m MIBI
Number of subjects: 39
Study: 9166128

Group type: EXPERIMENTAL
Intervention: 10 mg/m3 NMP
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 25 mg/m3 NMP
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 50 mg/m3 NMP
Number of subjects: 6

Group type: COMPARATOR
Intervention: NMP exposure
Number of subjects: 6
Study: 7702974

Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine (5 micrograms/kg/min) and isosorbide dinitrate (2 micrograms/kg/min) gated blood pool scintigraphy (GBPS)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Thallium SPECT with reinjection
Number of subjects: 38
Study: 3312176

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Fluoxetine (all doses)
Number of subjects: 84
Study: 29258631

Group type: EXPERIMENTAL
Intervention: CBGT + ABM
Number of subjects: 50

Group type: COMPARATOR
Intervention: CBGT + placebo
Number of subjects: 50
Study: 26797232

Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity program
Number of subjects: 260
Study: 26359996

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (54 to 64 U administered: GFL 20 U; HFL 10-20 U; LPL 24 U)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 23514285

Group type: EXPERIMENTAL
Intervention: Closure of patent foramen ovale with the Amplatzer PFO Occluder
Number of subjects: 414

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 414
Study: 20829306

Group type: EXPERIMENTAL
Intervention: CBD (400 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 18571340

Group type: EXPERIMENTAL
Intervention: Psychosocial therapies
Number of subjects: 2376
Study: 17167363

Group type: EXPERIMENTAL
Intervention: Intermittent self‐catheterization (ISC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Suprapubic catheterization (SPC)
Number of subjects: 40
Study: 15494910

Group type: EXPERIMENTAL
Intervention: Single 500-mg dose of azithromycin
Number of subjects: 93

Group type: COMPARATOR
Intervention: 1-week course of daily 200-mg dose of doxycycline
Number of subjects: 93
Study: 11032403

Group type: EXPERIMENTAL
Intervention: Twice-a-day IFN-beta injection (3 MU i.v. twice a day for 2 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Once-a-day IFN-beta injection (6 MU daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Twice-a-day IFN-beta injection
Number of subjects: 30
Study: 8721257

Group type: EXPERIMENTAL
Intervention: 50 mg riluzole
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 100 mg riluzole
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 200 mg riluzole
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1578063

Group type: EXPERIMENTAL
Intervention: Teaching intervention with follow-up telephone call
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 3904894

Group type: EXPERIMENTAL
Intervention: Ioxaglate (200 mg iodine/ml)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Angiografin (meglumine diatrizoate)
Number of subjects: 48
Study: 31325240

Group type: EXPERIMENTAL
Intervention: Exercise groups
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 6
Study: 30287610

Group type: EXPERIMENTAL
Intervention: Medication reduction (stopping one antihypertensive medication) with optional self-monitoring
Number of subjects: 540

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 540
Study: 27052961

Group type: EXPERIMENTAL
Intervention: 4 months monitoring
Number of subjects: 142

Group type: COMPARATOR
Intervention: 6 months monitoring
Number of subjects: 142
Study: 25046730

Group type: EXPERIMENTAL
Intervention: 1 mg of melatonin in soft gel capsules
Number of subjects: 60

Group type: COMPARATOR
Intervention: 3 mg of melatonin powder
Number of subjects: 60
Study: 20362711

Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab bolus application during PCI
Number of subjects: 1912

Group type: COMPARATOR
Intervention: Intravenous abciximab application during PCI
Number of subjects: 1912

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of abciximab for 12 hours post-PCI
Number of subjects: 1912
Study: 18267342

Group type: EXPERIMENTAL
Intervention: Echography assessment of tumors
Number of subjects: 2320

Group type: EXPERIMENTAL
Intervention: Echography assessment for extrascleral extension
Number of subjects: 2320
Study: 16699827

Group type: EXPERIMENTAL
Intervention: Caffeine and taurine pills
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12816784

Group type: EXPERIMENTAL
Intervention: 20 mg/d iron supplement (ferrous sulfate)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430
Study: 11466801

Group type: EXPERIMENTAL
Intervention: Parametric and semi-parametric sample selection estimators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Common support approach
Number of subjects: 0
Study: 9097068

Group type: EXPERIMENTAL
Intervention: 8-week depression treatment trial
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Additional courses of antidepressant therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 25
Study: 8200383

Group type: EXPERIMENTAL
Intervention: Adjuvant progestagen therapy
Number of subjects: 205

Group type: COMPARATOR
Intervention: No additional therapy (Control)
Number of subjects: 205
Study: 3808582

Group type: EXPERIMENTAL
Intervention: Healon (sodium hyaluronate)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control (no Healon)
Number of subjects: 114
Study: 29654027

Group type: EXPERIMENTAL
Intervention: Combined oral and intravenous antimicrobial prophylaxis
Number of subjects: 960

Group type: COMPARATOR
Intervention: Intravenous antibiotic prophylaxis alone
Number of subjects: 960
Study: 27741344

Group type: EXPERIMENTAL
Intervention: Dapsone gel, 7.5% (3 formulations: DAP-11078, DAP-11079, DAP-11080), applied once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dapsone gel, 5%, applied twice-daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All dapsone formulations (7.5% and 5%)
Number of subjects: 0
Study: 24943000

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 7034

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 7034

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7034

Group type: EXPERIMENTAL
Intervention: Empagliflozin (both doses pooled)
Number of subjects: 7034
Study: 23031516

Group type: EXPERIMENTAL
Intervention: Cu supplementation (15 mg Cu sulphate/kg dry matter)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-supplemented control
Number of subjects: 10
Study: 19661830

Group type: EXPERIMENTAL
Intervention: High supervision (HS, 1:5 coach to athlete ratio)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Low supervision (LS, 1:25 coach to athlete ratio)
Number of subjects: 124
Study: 18448618

Group type: EXPERIMENTAL
Intervention: Intranasal dose of 10(7) fluorescent focus units (FFU) of a live attenuated influenza virus vaccine (CAIV‐T)
Number of subjects: 2172

Group type: COMPARATOR
Intervention: Commercial inactivated influenza virus vaccine
Number of subjects: 2172

Group type: EXPERIMENTAL
Intervention: CAIV‐T
Number of subjects: 2172
Study: 15762092

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 512

Group type: COMPARATOR
Intervention: Amlodipine besilate
Number of subjects: 512
Study: 12682327

Group type: EXPERIMENTAL
Intervention: Click-evoked vestibulo-ocular reflex test at 110dB
Number of subjects: 13

Group type: COMPARATOR
Intervention: Normal subjects (control group)
Number of subjects: 13
Study: 11864918

Group type: EXPERIMENTAL
Intervention: Postmenopausal hormone treatment
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control (no hormone treatment)
Number of subjects: 86
Study: 10408993

Group type: EXPERIMENTAL
Intervention: Single oral dose of beta lactam antibiotics and erythromycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single oral dose of clindamycin, tetracycline, trimethoprim/sulfamethoxazole, and ciprofloxacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hospitalized patients receiving multiple drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 0
Study: 7749974

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (50 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Terfenadine (60 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (25 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (4 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (50 mg), Diphenhydramine (25 mg), Chlorpheniramine (4 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (50 mg) vs Chlorpheniramine (4 mg)
Number of subjects: 18
Study: 2210597

Group type: EXPERIMENTAL
Intervention: 120 mg isosorbide dinitrate in sustained-release form
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 6171572

Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon (HLI) at a daily dose of 10(6) units applied by contraceptive pessary technique for 14 days in patients with viral alterations and 21 days in those with changed cytologic findings.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified treatment).
Number of subjects: 0
Study: 6205924

Group type: EXPERIMENTAL
Intervention: Propafenon (300 mg three times daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dihydroquinidine Chloride (300 mg six times daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29277963

Group type: EXPERIMENTAL
Intervention: Basic foam mattress
Number of subjects: 15

Group type: COMPARATOR
Intervention: Reactive gel mattress
Number of subjects: 15

Group type: COMPARATOR
Intervention: Active alternating air mattress
Number of subjects: 15
Study: 27552171

Group type: EXPERIMENTAL
Intervention: XiangBin granules
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 3
Study: 24352484

Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 466

Group type: COMPARATOR
Intervention: Supine positioning
Number of subjects: 466
Study: 22935526

Group type: EXPERIMENTAL
Intervention: Clopidogrel loading dose 600 mg
Number of subjects: 1457

Group type: COMPARATOR
Intervention: Clopidogrel loading dose 300 mg
Number of subjects: 1457
Study: 20810171

Group type: EXPERIMENTAL
Intervention: Herpes simplex keratitis eyes
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Contralateral unaffected eyes
Number of subjects: 31

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: HSK eyes
Number of subjects: 31
Study: 17953950

Group type: EXPERIMENTAL
Intervention: 100 mg of oral nimesulide
Number of subjects: 440

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 440
Study: 17117562

Group type: EXPERIMENTAL
Intervention: Synthetic auricular point therapy (blood‐letting on the ear back, point injection of own blood, pricking ear point)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 108
Study: 12594142

Group type: EXPERIMENTAL
Intervention: Lidocaine 60 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ropivacaine 15 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 10 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (Ropivacaine and Levobupivacaine)
Number of subjects: 90
Study: 10976544

Group type: EXPERIMENTAL
Intervention: Sustained-release nifedipine
Number of subjects: 226
Study: 8833209

Group type: EXPERIMENTAL
Intervention: Femoral bone from patients with fractured neck of femur
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bone adjacent to joints with osteoarthrosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control bone (necropsy control group)
Number of subjects: 0
Study: 1422322

Group type: EXPERIMENTAL
Intervention: Ipriflavone (600 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 28
Study: 4074607

Group type: EXPERIMENTAL
Intervention: Conventional metoprolol 200 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Long-acting metoprolol 200 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31420920

Group type: EXPERIMENTAL
Intervention: High-dose aspirin (dual COX inhibition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard low-dose aspirin (selective COX-1 inhibition)
Number of subjects: 0
Study: 30238727

Group type: EXPERIMENTAL
Intervention: Adductor canal block combined with local infiltration anesthesia
Number of subjects: 104

Group type: COMPARATOR
Intervention: Intraoperative local infiltration anesthesia
Number of subjects: 104
Study: 27936941

Group type: EXPERIMENTAL
Intervention: Aliskiren (direct renin inhibitor)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Angiotensin II receptor blockers (ARB)
Number of subjects: 36
Study: 24262929

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 8mg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Tocilizumab (TCZ) 4mg/kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 22640229

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 50 µg
Number of subjects: 160

Group type: COMPARATOR
Intervention: Vaginal misoprostol 25 µg
Number of subjects: 160
Study: 20656153

Group type: EXPERIMENTAL
Intervention: Operating microscope angled 15 degrees nasal to the fovea (study group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group with operating microscope directly overhead around the optic disc region
Number of subjects: 30
Study: 18715407

Group type: EXPERIMENTAL
Intervention: Saline infusion sonography (SIS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Office hysteroscopy
Number of subjects: 100
Study: 15942186

Group type: EXPERIMENTAL
Intervention: Fluoride varnish treatment twice a year at 6-month intervals
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Fluoride varnish treatment 3 times a year within 1 week
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Fluoride varnish treatment 8 times per year during semesters with 1-month intervals
Number of subjects: 758

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Fluoride varnish treatment once a year
Number of subjects: 758
Study: 12589354

Group type: EXPERIMENTAL
Intervention: Desloratadine (5 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fexofenadine hydrochloride (180 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Levocetirizine dihydrochloride (5 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11097583

Group type: EXPERIMENTAL
Intervention: LASIK surgery
Number of subjects: 58